Amgen’s Anemia Drugs Weaken In First Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
“Trust us” on unchanged revenue guidance, CEO says.
You may also be interested in...
CHMP Recommends Three Approvals And Two Label Expansions, Makes One Denial
EMEA recommends against use of epoetins in some cancer patients.
CHMP Recommends Three Approvals And Two Label Expansions, Makes One Denial
EMEA recommends against use of epoetins in some cancer patients.
Amgen’s Aranesp Gets Broader Label
FDA provides small boost for safety-challenged ESA.